Welcome to our dedicated page for Avivagen news (Ticker: VIVXF), a resource for investors and traders seeking the latest updates and insights on Avivagen stock.
Avivagen Inc. (VIVXF) is a biotechnology innovator developing science-backed solutions for animal health through its proprietary OxC-beta™ technology. This dedicated news hub provides investors and industry professionals with essential updates on Avivagen's progress in creating non-antibiotic alternatives for livestock and companion animal nutrition.
Access authoritative reports on product developments, regulatory milestones, and strategic partnerships. Our curated feed includes verified announcements about clinical trial results, manufacturing expansions, and peer-reviewed research validating Avivagen's immune-support technologies.
Key updates cover three critical areas: scientific advancements in carotenoid-based solutions, commercial partnerships with global agriculture leaders, and regulatory progress across international markets. Each news item is vetted for relevance to long-term investors tracking sustainable alternatives in animal nutrition.
Bookmark this page for streamlined access to Avivagen's official communications and third-party analyses. Check regularly for developments shaping the future of antibiotic-free animal health solutions across pork, poultry, and dairy production systems worldwide.
Avivagen Inc. (TSXV: VIV, OTCQB: VIVXF) announces significant sales growth for its companion animal products, securing 6,000 orders from customers in Taiwan and Mexico. This includes a 1,500-unit order from a Taiwanese partner, marking their largest order this year. A new Mexican distributor ordered 4,000 units for its brand, with another order of 500 units to be marketed via veterinary clinics. The company’s Chief Financial Officer, Chris Boland, has departed, with a new CFO to be announced soon.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced the issuance of 878,000 stock options, predominantly to its officers, directors, and investor relations personnel. Of these, 685,000 options are allocated to these key roles, all exercisable over five years at a strike price of $0.20. This move is part of a broader remuneration strategy aimed at enhancing performance and commitment within the company.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) reported its financial results for Q2 2022, showing net revenues of $88,438, a significant decline from $159,614 in Q2 2021. The comprehensive loss decreased to $(1,303,677) from $(2,197,649) year-over-year. As of April 30, 2022, total assets stood at $3,013,537, with liabilities at $6,907,179, resulting in a shareholder deficit of $(3,893,642). The company continues to focus on its OxC-beta™ technology, promoting non-antibiotic growth solutions for livestock.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has completed crucial safety evaluations of its proprietary beta-carotene ingredient, OxBC, used in its OxC-beta™ product line for livestock and humans. The study confirms OxBC's safety and effectiveness, supporting its GRAS status in the U.S. and regulatory approvals in key markets like China and Brazil. Over 35 million livestock and 82,000 dogs have benefited from OxBC. The toxicology tests documented high maximum tolerated doses and no adverse effects, reinforcing OxBC's commercialization potential.
Avivagen Inc. (OTCQB: VIVXF) has signed a distribution agreement with Nong San Viet Co., Ltd to expand its market presence in Vietnam. This partnership will promote Avivagen's oxidized carotenoid-based feed additives, which enhance animal health and performance. Vietnam is highlighted as a major opportunity, being the largest feed market in Southeast Asia, with total feed consumption exceeding 32 million metric tons in 2020. The agreement follows regulatory approvals and aims to leverage growing interest from local producers.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has secured regulatory approval for its oxidized carotenoid-based feed additive, OxC-beta™, for use in China. This strategic entry allows Avivagen to access the world's largest feed market, critical for the company's growth. The approval resulted from collaboration with COFCO Biotech and follows successful trials across various livestock species. With China leading global feed production and a significant push to reduce antibiotic use, Avivagen’s product positions itself as a viable alternative, potentially transforming their market presence in Asia and beyond.
Avivagen Inc. (OTCQB:VIVXF) reported key advancements in global adoption of OxC-beta™ technology, including a supply agreement with AB Vista for the U.S., Brazil, and Thailand. Positive results from animal trials have led to new customer acquisitions and increased scientific recognition. Shareholders supported all resolutions during the annual general meeting, with significant director election support. The company aims to enhance market reach while navigating challenges posed by the pandemic, signaling strong growth potential for OxC-beta™ in livestock feed markets.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) reported its unaudited financial results for the first quarter ended
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) will present at the Annual Alpha North Capital Event in the Bahamas from March 25-27, 2022. This invite-only conference connects growth-stage companies with capital finance professionals through one-on-one meetings and networking. Avivagen focuses on products that enhance feed intake and immune function in livestock, companion animals, and humans. The company is known for its OxC-beta™ technology, a non-antibiotic solution promoting health in livestock, which is currently available in several countries.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced a significant order for its OxC-beta Livestock™ product from a leading poultry producer in Mexico. Successful evaluation trials showed productivity and health improvements using OxC-beta. The small initial order sets the stage for larger future orders, enhancing Avivagen's market presence in Mexico. The company anticipates a recurring revenue stream from this customer, who is part of a major producer association. The Mexican animal feed market is projected to exceed US$8 billion by 2025, driven by the poultry sector.
